Erbitux Revised Deal Puts Bristol In Charge Of ImClone’s FDA Discussions
Executive Summary
Bristol is assuming leadership of ImClone's discussions with FDA regarding resubmission of its colorectal cancer treatment Erbitux according to a revised agreement between the two companies